Secretary of HHS Extends COVID-19 Public Health Emergency

April 14, 2022

Effective April 16, 2022, Secretary of Health and Human Services (HHS) Xavier Becerra renewed the COVID-19 public health emergency that has existed nationwide since January 27, 2020.

For more information, visit the HSS website.

Posted 4/14/2022

Upcoming Events

ACCC Oncology Reimbursement Meeting | Reno

In Person November 4, 2026 at 8:00 AM PST255 North Virginia Street, Reno, NV, USAWhitney Peak Hotel Reno, Tapestry Collection by Hilton,

ACCC Oncology Reimbursement Meeting | Providence

In Person November 10, 2026 at 8:00 AM EST5 Avenue of the Arts, Providence, RI, USARenaissance Providence Downtown Hotel,

Trending Now on
ACCCBuzz Blog

Clear Pathways to Care: APPs and AHPs Expanding Access at the Wilmot Cancer Institute’s Breast Care Program

By championing and encouraging advanced practice providers and allied health professionals to work at the top of their licenses, Wilmot Cancer Institute offers comprehensive care close to home through its breast care program that vastly improves the patient experience.

#ACCCNOC: Care Between Visits, Removing Financial Barriers, and Policy Initiatives

On the final day of the 43rd National Oncology Conference, a series of interactive panel discussions explored innovative strategies for remote patient monitoring across the globe, improving quality and safety amidst complex treatments, financial challenges in precision medicine and clinical trials, and more.

Secretary of HHS Extends COVID-19 Public Health Emergency

Related Content

FDA Approves Zenocutuzumab-zbco for Advanced, Unresectable, or Metastatic Cholangiocarcinoma

FDA Approves Vepdegestrant for ER-positive, HER2-negative, ESR1-mutated Advanced or Metastatic Breast Cancer

Upcoming Events

ACCC Oncology Reimbursement Meeting | Reno

ACCC Oncology Reimbursement Meeting | Providence

Trending Now on
ACCCBuzz Blog

Clear Pathways to Care: APPs and AHPs Expanding Access at the Wilmot Cancer Institute’s Breast Care Program

#ACCCNOC: Care Between Visits, Removing Financial Barriers, and Policy Initiatives

FDA Approves Relacorilant With Nab-paclitaxel for Platinum-resistant Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

FDA Approves Nivolumab With Chemotherapy for Previously Untreated Hodgkin Lymphoma

FDA Approves Teclistamab in Combination With Daratumumab Hyaluronidase-fihj for Relapsed or Refractory Multiple Myeloma

FDA Grants Accelerated Approval to Zongertinib for Unresectable or Metastatic Non-squamous Non-small Cell Lung Cancer

FDA Grants Traditional Approval to Encorafenib for Metastatic Colorectal Cancer With a BRAF V600E Mutation

FDA Approves Acalabrutinib With Venetoclax for Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

#ACCCNOC: Igniting Innovation, Operationalizing CAR T and Bispecifics, and Whole-Person Support

#ACCCNOC: The Psychosocial Oncology Professionals Symposium, the ACCC Presidential Address, and the 2026 ACCC Innovators

Recently Heard on
CANCER BUZZ Podcast

Live from NOC: Dr. Doug Flora's Presidential Address

Not a Revolution, an Evolution: AI and the Future of Cancer Care – [Video Podcast] Ep. 67

The Financial Reality of Bispecific Antibodies: What It Takes to Build and Sustain a Program - Podcast [Ep. 243]

Bringing CAR T-Cell Therapy to the Community Setting - Mini Podcast [Ep. 242]

Latest from Oncology Issues

Join the Conversation

Secretary of HHS Extends COVID-19 Public Health Emergency

Related Content

FDA Approves Zenocutuzumab-zbco for Advanced, Unresectable, or Metastatic Cholangiocarcinoma

FDA Approves Vepdegestrant for ER-positive, HER2-negative, ESR1-mutated Advanced or Metastatic Breast Cancer

Upcoming Events

ACCC Oncology Reimbursement Meeting | Reno

ACCC Oncology Reimbursement Meeting | Providence

Trending Now on ACCCBuzz Blog

Clear Pathways to Care: APPs and AHPs Expanding Access at the Wilmot Cancer Institute’s Breast Care Program

#ACCCNOC: Care Between Visits, Removing Financial Barriers, and Policy Initiatives

FDA Approves Relacorilant With Nab-paclitaxel for Platinum-resistant Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

FDA Approves Nivolumab With Chemotherapy for Previously Untreated Hodgkin Lymphoma

FDA Approves Teclistamab in Combination With Daratumumab Hyaluronidase-fihj for Relapsed or Refractory Multiple Myeloma

FDA Grants Accelerated Approval to Zongertinib for Unresectable or Metastatic Non-squamous Non-small Cell Lung Cancer

FDA Grants Traditional Approval to Encorafenib for Metastatic Colorectal Cancer With a BRAF V600E Mutation

FDA Approves Acalabrutinib With Venetoclax for Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

#ACCCNOC: Igniting Innovation, Operationalizing CAR T and Bispecifics, and Whole-Person Support

#ACCCNOC: The Psychosocial Oncology Professionals Symposium, the ACCC Presidential Address, and the 2026 ACCC Innovators

Recently Heard on CANCER BUZZ Podcast

Live from NOC: Dr. Doug Flora's Presidential Address

Not a Revolution, an Evolution: AI and the Future of Cancer Care – [Video Podcast] Ep. 67

The Financial Reality of Bispecific Antibodies: What It Takes to Build and Sustain a Program - Podcast [Ep. 243]

Bringing CAR T-Cell Therapy to the Community Setting - Mini Podcast [Ep. 242]

Latest from Oncology Issues

Join the Conversation

Trending Now on
ACCCBuzz Blog

Recently Heard on
CANCER BUZZ Podcast